NORTH AMERICA IMMUNOGLOBULIN MARKET 2022-2028

 

TABLE OF CONTENTS

1.     NORTH AMERICA IMMUNOGLOBULIN MARKET – SUMMARY

2.     INDUSTRY OUTLOOK

2.1. IMPACT OF COVID-19 ON THE IMMUNOGLOBULIN MARKET

2.2. KEY INSIGHTS

2.2.1.    DEVELOPMENT OF NEW PURIFICATION METHODS

2.2.2.    INCREASING PREFERENCE FOR PERSONALIZED MEDICINES

2.3. PORTER’S FIVE FORCES ANALYSIS

2.3.1.    THREAT OF NEW ENTRANTS

2.3.2.    THREAT OF SUBSTITUTES

2.3.3.    BARGAINING POWER OF BUYERS

2.3.4.    BARGAINING POWER OF SUPPLIERS

2.3.5.    THREAT OF COMPETITIVE RIVALRY

2.4. MARKET ATTRACTIVENESS INDEX

2.5. VENDOR SCORECARD

2.6. KEY MARKET STRATEGIES

2.6.1.    PRODUCT LAUNCHES & DEVELOPMENTS

2.6.2.    PARTNERSHIPS & AGREEMENTS

2.7. MARKET DRIVERS

2.7.1.    GROWTH IN THE GERIATRIC POPULATION

2.7.2.    PREVALENCE OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS

2.7.3.    INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES

2.8. MARKET CHALLENGES

2.8.1.    HIGH COST OF THERAPY

2.8.2.    HIGH RISK OF SIDE EFFECTS DUE TO THE USE OF IMMUNOGLOBULIN

2.9. MARKET OPPORTUNITIES

2.9.1.    INCREASING ADOPTION OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) TREATMENTS

2.9.2.    GROWING CLINICAL TRIALS

3.     NORTH AMERICA IMMUNOGLOBULIN MARKET OUTLOOK – BY TYPE

3.1. IGG

3.2. IGA

3.3. IGM

3.4. IGE

3.5. IGD

4.     NORTH AMERICA IMMUNOGLOBULIN MARKET OUTLOOK - BY DELIVERY MODE

4.1. INTRAVENOUS

4.2. SUBCUTANEOUS

4.3. INTRAMUSCULAR

5.     NORTH AMERICA IMMUNOGLOBULIN MARKET OUTLOOK – BY APPLICATION

5.1. HYPOGAMMA GLOBULINEMIA

5.2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

5.3. PRIMARY IMMUNODEFICIENCY DISEASES

5.4. MYASTHENIA GRAVIS

5.5. MULTIFOCAL MOTOR NEUROPATHY

5.6. IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

5.7. INFLAMMATORY MYOPATHIES

5.8. SPECIFIC ANTIBODY DEFICIENCY

5.9. GUILLAIN-BARRE SYNDROME

5.10.               OTHER APPLICATIONS

6.     NORTH AMERICA IMMUNOGLOBULIN MARKET OUTLOOK – BY END-USER

6.1. HOSPITALS & CLINICS

6.2. HOMECARE

7.     NORTH AMERICA IMMUNOGLOBULIN MARKET OUTLOOK – BY SALES CHANNEL

7.1. HOSPITAL PHARMACY

7.2. SPECIALTY PHARMACY

7.3. OTHER SALES CHANNELS

8.     NORTH AMERICA IMMUNOGLOBULIN MARKET – COUNTRY OUTLOOK

8.1. UNITED STATES

8.2. CANADA

9.     COMPETITIVE LANDSCAPE

9.1. BIOTEST AG

9.2. CHINA BIOLOGIC PRODUCTS INC

9.3. GRIFOLS SA

9.4. LFB GROUP

9.5. CSL BEHRING

9.6. KEDRION BIOPHARMA

9.7. OCTAPHARMA AG

9.8. TAKEDA PHARMACEUTICAL COMPANY LIMITED

9.9. BIO PRODUCTS LABORATORY

9.10.               SHANGHAI RAAS BLOOD PRODUCTS CO LTD

9.11.               PFIZER INC

9.12.               SANQUIN PLASMA PRODUCTS BV

9.13.               ADMA BIOLOGICS

9.14.               SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD

9.15.               KAMADA LTD

10. RESEARCH METHODOLOGY & SCOPE

10.1.               RESEARCH SCOPE & DELIVERABLES

10.2.               SOURCES OF DATA

10.3.               RESEARCH METHODOLOGY

 

TABLE LIST

TABLE 1: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 2: VENDOR SCORECARD

TABLE 3: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)

TABLE 4: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)

TABLE 5: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)

TABLE 6: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)

TABLE 7: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)

TABLE 8: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

 

FIGURE LIST

FIGURE 1: MARKET ATTRACTIVENESS INDEX

FIGURE 2: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY TYPE, 2021 & 2028 (IN %)

FIGURE 3: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY IGG, 2022-2028 (IN $ MILLION)

FIGURE 4: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY IGA, 2022-2028 (IN $ MILLION)

FIGURE 5: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY IGM, 2022-2028 (IN $ MILLION)

FIGURE 6: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY IGE, 2022-2028 (IN $ MILLION)

FIGURE 7: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY IGD, 2022-2028 (IN $ MILLION)

FIGURE 8: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2021 & 2028 (IN %)

FIGURE 9: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY INTRAVENOUS, 2022-2028 (IN $ MILLION)

FIGURE 10: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS, 2022-2028 (IN $ MILLION)

FIGURE 11: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR, 2022-2028 (IN $ MILLION)

FIGURE 12: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2021 & 2028 (IN %)

FIGURE 13: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2028 (IN $ MILLION)

FIGURE 14: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, 2022-2028 (IN $ MILLION)

FIGURE 15: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2028 (IN $ MILLION)

FIGURE 16: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2028 (IN $ MILLION)

FIGURE 17: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2028 (IN $ MILLION)

FIGURE 18: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), 2022-2028 (IN $ MILLION)

FIGURE 19: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2028 (IN $ MILLION)

FIGURE 20: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2028 (IN $ MILLION)

FIGURE 21: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2028 (IN $ MILLION)

FIGURE 22: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2028 (IN $ MILLION)

FIGURE 23: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY END-USER, 2021 & 2028 (IN %)

FIGURE 24: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2028 (IN $ MILLION)

FIGURE 25: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2028 (IN $ MILLION)

FIGURE 26: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2021 & 2028 (IN %)

FIGURE 27: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2028 (IN $ MILLION)

FIGURE 28: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2028 (IN $ MILLION)

FIGURE 29: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY OTHER SALES CHANNELS, 2022-2028 (IN $ MILLION)

FIGURE 30: NORTH AMERICA IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)

FIGURE 31: UNITED STATES IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 32: CANADA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

 

Presence of leading market players and growing product approvals are factors promoting immunoglobulin adoption in North America

 

MARKET OUTLOOK

According to Triton’s research report, immunoglobulin in North America is likely to grow with a CAGR of 6.85% over the projected duration from 2022 to 2028. Canada and the United States are the countries included in the market in this region.

Due to the increased risk of various diseases in the United States and Canada, the immunoglobulin market in the North American region is growing. The high prevalence of various diseases among people in the US and rising FDA approvals are some of the key elements anticipated to support the expansion of the immunoglobulin market in the country throughout the forecast period.

Furthermore, it is anticipated that an increase in product approvals by the US Food and Drug Administration will increase the demand and adoption of immunoglobulin products in the region. The United States has a number of well-known industry players, which opens up opportunities for technological and product development advances in the field of  immunoglobulins.

During the projected period, the rising prevalence of diseases is one of the key factors anticipated to support the growth of the immunoglobulin market in Canada. Additionally, there has been a large expansion of the immunoglobulin and plasma infrastructure across Canada recently, which is anticipated to have a favorable effect on the market’s expansion over the years to come.

 

Get more insights into the North America Immunoglobulin Market:

 

https://www.tritonmarketresearch.com/reports/north-america-immunoglobulin-market

 

COMPETITIVE OUTLOOK

Grifols SA, Takeda Pharmaceutical Company Limited, ADMA Biologics, LFB Group, Kamada Ltd, Octapharma AG, Sanquin Plasma Products BV, Bio Products Laboratory, and CSL Behring are some of the biggest names in the immunoglobulin market.

 

SEGMENTATION

1.     BIOTEST AG

2.     CHINA BIOLOGIC PRODUCTS INC

3.     GRIFOLS SA

4.     LFB GROUP

5.     CSL BEHRING

6.     KEDRION BIOPHARMA

7.     OCTAPHARMA AG

8.     TAKEDA PHARMACEUTICAL COMPANY LIMITED

9.     BIO PRODUCTS LABORATORY

10. SHANGHAI RAAS BLOOD PRODUCTS CO LTD

11. PFIZER INC

12. SANQUIN PLASMA PRODUCTS BV

13. ADMA BIOLOGICS

14. SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD

15. KAMADA LTD